[1]
Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF. Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients. Advances in therapy. 2016 Mar:33(3):345-56. doi: 10.1007/s12325-016-0292-y. Epub 2016 Feb 23
[PubMed PMID: 26905265]
Level 3 (low-level) evidence
[2]
Sellarés J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012 Feb:12(2):388-99. doi: 10.1111/j.1600-6143.2011.03840.x. Epub 2011 Nov 14
[PubMed PMID: 22081892]
Level 3 (low-level) evidence
[3]
Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation. 2006 Mar 15:81(5):643-54
[PubMed PMID: 16534463]
Level 3 (low-level) evidence
[4]
Becker LE,Morath C,Suesal C, Immune mechanisms of acute and chronic rejection. Clinical biochemistry. 2016 Mar;
[PubMed PMID: 26851348]
[5]
Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2007 Mar:7(3):518-26
[PubMed PMID: 17352710]
[6]
Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, Nankivell BJ, Halloran PF, Colvin RB, Akalin E, Alachkar N, Bagnasco S, Bouatou Y, Becker JU, Cornell LD, Duong van Huyen JP, Gibson IW, Kraus ES, Mannon RB, Naesens M, Nickeleit V, Nickerson P, Segev DL, Singh HK, Stegall M, Randhawa P, Racusen L, Solez K, Mengel M. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2018 Feb:18(2):293-307. doi: 10.1111/ajt.14625. Epub 2018 Jan 21
[PubMed PMID: 29243394]
[7]
Hara S. Current pathological perspectives on chronic rejection in renal allografts. Clinical and experimental nephrology. 2017 Dec:21(6):943-951. doi: 10.1007/s10157-016-1361-x. Epub 2016 Nov 16
[PubMed PMID: 27848058]
Level 3 (low-level) evidence
[8]
El Ters M, Grande JP, Keddis MT, Rodrigo E, Chopra B, Dean PG, Stegall MD, Cosio FG. Kidney allograft survival after acute rejection, the value of follow-up biopsies. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013 Sep:13(9):2334-41. doi: 10.1111/ajt.12370. Epub 2013 Jul 19
[PubMed PMID: 23865852]
[9]
Lorenz EC, Smith BH, Cosio FG, Schinstock CA, Shah ND, Groehler PN, Verdick JS, Park WD, Stegall MD. Long-term Immunosuppression Adherence After Kidney Transplant and Relationship to Allograft Histology. Transplantation direct. 2018 Oct:4(10):e392. doi: 10.1097/TXD.0000000000000824. Epub 2018 Sep 7
[PubMed PMID: 30498769]
[11]
Messa P, Regalia A, Alfieri CM. Nutritional Vitamin D in Renal Transplant Patients: Speculations and Reality. Nutrients. 2017 May 27:9(6):. doi: 10.3390/nu9060550. Epub 2017 May 27
[PubMed PMID: 28554998]
[12]
Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation. 2004 Jul 27:78(2):242-9
[PubMed PMID: 15280685]
[13]
Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010 Jul 15:90(1):68-74. doi: 10.1097/TP.0b013e3181e065de. Epub
[PubMed PMID: 20463643]
[14]
Stegall MD, Park WD, Larson TS, Gloor JM, Cornell LD, Sethi S, Dean PG, Prieto M, Amer H, Textor S, Schwab T, Cosio FG. The histology of solitary renal allografts at 1 and 5 years after transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2011 Apr:11(4):698-707. doi: 10.1111/j.1600-6143.2010.03312.x. Epub 2010 Nov 9
[PubMed PMID: 21062418]
[15]
Halloran PF. T cell-mediated rejection of kidney transplants: a personal viewpoint. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2010 May:10(5):1126-34. doi: 10.1111/j.1600-6143.2010.03053.x. Epub 2010 Mar 23
[PubMed PMID: 20346061]
[16]
Pascual J, Pérez-Sáez MJ, Mir M, Crespo M. Chronic renal allograft injury: early detection, accurate diagnosis and management. Transplantation reviews (Orlando, Fla.). 2012 Oct:26(4):280-90. doi: 10.1016/j.trre.2012.07.002. Epub 2012 Aug 17
[PubMed PMID: 22902496]
[17]
Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. Journal of the American Society of Nephrology : JASN. 2005 Oct:16(10):3015-26
[PubMed PMID: 16120819]
[18]
Stegall MD, Gaston RS, Cosio FG, Matas A. Through a glass darkly: seeking clarity in preventing late kidney transplant failure. Journal of the American Society of Nephrology : JASN. 2015 Jan:26(1):20-9. doi: 10.1681/ASN.2014040378. Epub 2014 Aug 5
[PubMed PMID: 25097209]
[19]
Marqués GG, Goenaga PE, Royo FJ, Escolá JM, García Fernández N, Unanua AP. Evolution of the renal function is a better predictor of long-term survival than serum creatinine. Transplantation proceedings. 2005 Nov:37(9):3701-4
[PubMed PMID: 16386511]
[20]
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2009 Nov:9 Suppl 3():S1-155. doi: 10.1111/j.1600-6143.2009.02834.x. Epub
[PubMed PMID: 19845597]
Level 1 (high-level) evidence
[21]
Wiebe C, Nickerson P. Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Current opinion in organ transplantation. 2013 Aug:18(4):470-7. doi: 10.1097/MOT.0b013e3283626149. Epub
[PubMed PMID: 23695596]
Level 3 (low-level) evidence
[22]
Radermacher J, Mengel M, Ellis S, Stuht S, Hiss M, Schwarz A, Eisenberger U, Burg M, Luft FC, Gwinner W, Haller H. The renal arterial resistance index and renal allograft survival. The New England journal of medicine. 2003 Jul 10:349(2):115-24
[PubMed PMID: 12853584]
[23]
Schwenger V, Korosoglou G, Hinkel UP, Morath C, Hansen A, Sommerer C, Dikow R, Hardt S, Schmidt J, Kücherer H, Katus HA, Zeier M. Real-time contrast-enhanced sonography of renal transplant recipients predicts chronic allograft nephropathy. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2006 Mar:6(3):609-15
[PubMed PMID: 16468973]
[24]
Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC, David DS, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris AB 3rd, Gibson IW, Kraus E, Liapis H, Loupy A, Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M, Banff meeting report writing committee. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2014 Feb:14(2):272-83. doi: 10.1111/ajt.12590. Epub
[PubMed PMID: 24472190]
[25]
Hidalgo LG, Sis B, Sellares J, Campbell PM, Mengel M, Einecke G, Chang J, Halloran PF. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2010 Aug:10(8):1812-22. doi: 10.1111/j.1600-6143.2010.03201.x. Epub
[PubMed PMID: 20659089]
[26]
Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. The New England journal of medicine. 2002 Feb 21:346(8):580-90
[PubMed PMID: 11856798]
[27]
Sawinski D, Trofe-Clark J, Leas B, Uhl S, Tuteja S, Kaczmarek JL, French B, Umscheid CA. Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2016 Jul:16(7):2117-38. doi: 10.1111/ajt.13710. Epub 2016 Mar 15
[PubMed PMID: 26990455]
Level 1 (high-level) evidence
[28]
Camilleri B, Bridson JM, Halawa A. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 2016 Oct:14(5):471-483. doi: 10.6002/ect.2015.0283. Epub 2015 May 17
[PubMed PMID: 27213490]
[29]
Grimbert P, Thaunat O. mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now? Transplant international : official journal of the European Society for Organ Transplantation. 2017 Jul:30(7):647-657. doi: 10.1111/tri.12975. Epub
[PubMed PMID: 28445619]
[30]
Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP. Belatacept and Long-Term Outcomes in Kidney Transplantation. The New England journal of medicine. 2016 Jan 28:374(4):333-43. doi: 10.1056/NEJMoa1506027. Epub
[PubMed PMID: 26816011]
[31]
Ritz E, Wanner C. Statin use prolongs patient survival after renal transplantation. Journal of the American Society of Nephrology : JASN. 2008 Nov:19(11):2037-40. doi: 10.1681/ASN.2008090925. Epub 2008 Oct 8
[PubMed PMID: 18842988]
[32]
Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2007 Oct:7(10):2350-60
[PubMed PMID: 17845569]
Level 1 (high-level) evidence
[33]
Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. Journal of the American Society of Nephrology : JASN. 2006 Mar:17(3):889-99
[PubMed PMID: 16481415]
[34]
Opelz G, Zeier M, Laux G, Morath C, Döhler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. Journal of the American Society of Nephrology : JASN. 2006 Nov:17(11):3257-62
[PubMed PMID: 17035607]
[35]
Ibrahim HN, Jackson S, Connaire J, Matas A, Ney A, Najafian B, West A, Lentsch N, Ericksen J, Bodner J, Kasiske B, Mauer M. Angiotensin II blockade in kidney transplant recipients. Journal of the American Society of Nephrology : JASN. 2013 Feb:24(2):320-7. doi: 10.1681/ASN.2012080777. Epub 2013 Jan 10
[PubMed PMID: 23308016]
[36]
Denisov V, Zakharov V, Ksenofontova A, Onishchenko E, Golubova T, Kichatyi S, Zakharova O. Clinical Course and Outcomes of Late Kidney Allograft Dysfunction. Journal of transplantation. 2016:2016():7401808. doi: 10.1155/2016/7401808. Epub 2016 Jul 10
[PubMed PMID: 27478631]
[37]
Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2002 Nov:2(10):970-4
[PubMed PMID: 12482151]
[38]
Bunthof KLW, Hazzan M, Hilbrands LB. Review: Management of patients with kidney allograft failure. Transplantation reviews (Orlando, Fla.). 2018 Jul:32(3):178-186. doi: 10.1016/j.trre.2018.03.001. Epub 2018 Mar 29
[PubMed PMID: 29628415]